Apotex Pty Ltd v AstraZeneca AB (No 5)

Link copied
Case Copied 17 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v AstraZeneca AB (No 5) [2013] FCA 560  

Citation: Apotex Pty Ltd v AstraZeneca AB (No 5) [2013] FCA 560
Parties:

APOTEX PTY LTD v ASTRAZENECA AB and ASTRAZENECA PTY LIMITED

WATSON PHARMA PTY LTD v ASTRAZENECA AB and ASTRAZENECA PTY LIMITED

ASTRAZENECA AB and ASTRAZENECA PTY LIMITED v ASCENT PHARMA PTY LTD ACN 118 734 795

File number(s): NSD 673 of 2011
NSD 2342 of 2011
NSD 208 of 2012
Judge: JAGOT J
Date of judgment: 11 June 2013
Catchwords: PATENTS – costs – further orders of invalidity
Legislation: Federal Court Rules 2011 (Cth)
Cases cited: Apotex Pty Ltd v AstraZeneca AB (No 4) [2013] FCA 162
Bradken Resources v Lynx Engineering Consultants (No. 2) [2012] FCA 1478
Doric Products v Lockwood Security (2002) 54 IPR 495; [2002] FCA 282
In NSD 673 of 2011:
Counsel for the Applicant: Mr A J Maryniak
Solicitor for the Applicant: Herbert Smith Freehills
Counsel for the Respondents: Mr D Kell
Solicitor for the Respondents: Ashurst Australia
In NSD 2342 of 2011:
Counsel for the Applicant: Mr A J Ryan SC and Mr I P Horak
Solicitor for the Applicant: King & Wood Mallesons
Counsel for the Respondents: Mr D Kell
Solicitor for the Respondents: Ashurst Australia
In NSD 208 of 2012:
Counsel for the Applicants: Mr D Kell
Solicitor for the Applicants: Ashurst Australia
Counsel for the Respondent: Mr A J Ryan SC and Mr I P Horak
Solicitor for the Respondent: King & Wood Mallesons

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 673 of 2011

BETWEEN:

APOTEX PTY LTD
Applicant/Cross Respondent

AND:

ASTRAZENECA AB
First Respondent/Cross Claimants

ASTRAZENECA PTY LIMITED
Second Respondent/Cross-Claimants

JUDGE:

JAGOT J

DATE OF ORDER:

5 MARCH 2013

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Apotex Pty Limited (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed, excluding the costs of Apotex Pty Limited incurred in connection with its application for indemnity costs.

2.To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 2342 of 2011

BETWEEN:

WATSON PHARMA PTY LTD

Applicant/Cross Respondent

AND:

ASTRAZENECA AB
First Respondent/Cross Claimant

ASTRAZENECA PTY LIMITED
Second Respondent/Cross Claimant

JUDGE:

JAGOT J

DATE OF ORDER:

5 MARCH 2013

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.Subject to order 2 below:

a.Claims 6 and 19 to 25 of Australian Patent No 2000051842 (the “842” Patent”) be revoked;

b.Claims 11 to 20, 22 and 23 of Australian Patent No 2002214165 (the “165” Patent”) be revoked.

2.Order 1 be stayed:

a.Initially for a period of…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v AstraZeneca AB (No 5) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 560
Decision Date

CaseChat Overview and Summary

In Apotex Pty Ltd v AstraZeneca AB (No 5), the Federal Court of Australia addressed issues related to costs and the validity of patents. The case involved disputes between Apotex Pty Ltd and AstraZeneca AB, primarily concerning the costs incurred during the proceedings and the validity of certain patents held by AstraZeneca. The court was required to decide on AstraZeneca's submission for an apportionment of costs, effectively reducing the costs of Apotex, Watson Pharma, and Ascent by 25%, and Apotex's claim for indemnity costs against AstraZeneca.

The court first considered the applicable rules governing the proceedings. The case was initiated in May 2011 under the previous Federal Court Rules, but later expanded to include additional patents, with all significant procedural steps occurring after the implementation of the new Federal Court Rules in August 2011. The court held that the new rules should apply to the proceedings, including the offers of compromise made by Apotex. The court concluded that there was no basis to apply the old rules, as all offers of compromise were made under the new rules. The court further ruled that the new rules were not less generous to a party making an offer to settle the proceedings and that Apotex's offers were explicitly made in accordance with the new rules.

The court ordered that AstraZeneca AB and AstraZeneca Pty Ltd were to pay the costs of Apotex, Watson Pharma, and Ascent, excluding the costs incurred by Apotex in connection with its application for indemnity costs. The court also granted leave for the AstraZeneca parties to appeal the orders for costs and the revocation of certain patent claims. The revocation of specific claims of the patents held by AstraZeneca was stayed for 21 days, or until the final determination of any appeal, if lodged within that period. The orders provided for the revocation of claims 6 and 19 to 25 of Australian Patent No 2000051842 and claims 11 to 20, 22, and 23 of Australian Patent No 2002214165, contingent on the outcome of any appeals.

Orders

Orders of the court

1. Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Apotex Pty Limited (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed, excluding the costs of Apotex Pty Limited incurred in connection with its application for indemnity costs.

2. To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

1. Subject to order 2 below:

a. Claims 6 and 19 to 25 of Australian Patent No 2000051842 (the “842” Patent”) be revoked;

b. Claims 11 to 20, 22 and 23 of Australian Patent No 2002214165 (the “165” Patent”) be revoked.

2. Order 1 be stayed:

a. Initially for a period of 21 days from the date on which these orders are pronounced; and

b. If an appeal is lodged within that period, until the final determination of that appeal, or further order.

3. To the extent necessary, leave is granted to the AstraZeneca parties to appeal order 1 above.

4. Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Watson Pharma Pty Ltd (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed.

5. To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

6. Subject to order 2 below:

a. Claims 6 and 19 to 25 of Australian Patent No 2000051842 (the “842” Patent”) be revoked;

b. Claims 11 to 20, 22 and 23 of Australian Patent No 2002214165 (the “165” Patent”) be revoked.

7. Order 1 be stayed:

a. Initially for a period of 21 days from the date on which these orders are pronounced; and

b. If an appeal is lodged within that period, until the final determination of that appeal, or further order.

8. To the extent necessary, leave is granted to the AstraZeneca parties to appeal order 1 above.

9. Subject to any costs orders already made by the Court, AstraZeneca AB and AstraZeneca Pty Ltd pay the costs of Ascent Pharma Pty Ltd (including all reserved costs and the costs of and incidental to the hearing in relation to costs) of the proceedings, as agreed or taxed.

10. To the extent necessary, the parties are granted leave to appeal in respect of the orders for costs made today.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

On 5 March 2013, I delivered judgment in these proceedings, being Apotex Pty Ltd v AstraZeneca AB (No 4) [2013] FCA 162 (principal reasons for judgment). These reasons concern the costs orders and further orders for invalidity which should be made consequent upon that decision.Costs Two claims were put before me in respect of costs. First, AstraZeneca submitted that there should be an apportionment of costs, in effect, reducing the costs of Apotex, Watson Pharma and Ascent (the generic parties) by 25 per cent to take account of the issues at trial in respect of which it might fairly be said the generic parties did not succeed. Second, Apotex claimed indemnity costs against AstraZeneca. The first issue, primarily relating to the indemnity costs claim, is the applicable rules. The proceedings were commenced in May 2011 in respect of what I have called in the principal reasons for judgment the 051 or low dose patent. As at May 2011 the previous form of the Federal Court Rules was in force. The Federal Court Rules 2011 (Cth) (the new rules) in accordance with r 1.04(1) apply to a proceeding started in the Court on or after 1 August 2011. Rule 1.04(2) provides that the new rules also apply to a step in a proceeding that was started before 1 August 2011 if the step is taken on or after 1 August 2011. Rule 1.04(3) provides, however, that the court may order that the Federal Court Rules as in force immediately before 1 August 2011 apply with or without modification to a step mentioned in subr (2). After August 2011 and the coming into force of the new rules these proceedings were expanded to incorporate allegations of infringement and validity in respect of both the 165 or HeFH patent and the 842 or cation patent, with those patents being brought into the proceedings in December 2011 and January 2012. The offers of compromise or Calderbank offers sent by Apotex consist of two letters dated 24 January 2012, two letters dated 7 September 2012, with formal notices of offers of compromise thereafter served under cover of a letter dated 13 September 2012. In other words, it is apparent that although the proceedings were commenced in May 2011 in respect of one of the patents, the vast majority of the proceedings was conducted at a time when the new rules were in force and, more to the point, all of the letters offering to settle the proceedings and notices of offers of compromise were sent when the new rules were in force. I do not see any reason in these circumstances to make an order that the old rules apply. I do not accept that it is sufficient reason to make such an order that the new rules might be perceived as less generous to a party making an offer to settle proceedings than the old rules in the circumstances of this case. The fact is that all of the offers to which I have referred were made at a time when the new rules were in force. There is no evidentiary foundation to draw any inference that Apotex might have been operating on the basis that its offers of compromise should be dealt with pursuant to the old as opposed to the new rules. To the contrary, at least in respect of the formal offers of compromise dated 13 September 2012, there is express reference to the offers being made in accordance with the new rules.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.